{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:58:35Z","timestamp":1792789115788,"version":"4.5.0"},"reference-count":38,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea","award":["410087"],"award-info":[{"award-number":["410087"]}],"id":[{"id":"https:\/\/ror.org\/00wzhv093","id-type":"ROR","asserted-by":"crossref"}]},{"award":["410087"],"award-info":[{"award-number":["410087"]}],"id":[{"id":"https:\/\/ror.org\/00wzhv093","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Baseline HbA1c is expected to dominate prediction of subsequent HbA1c status; therefore, the clinically relevant question is whether additional routinely available variables provide reproducible incremental value. Methods: This retrospective longitudinal study used 809 records from adults with type 2 diabetes receiving routine outpatient care. Six-month HbA1c was available for 808 participants. The primary outcome was six-month glycemic status (HbA1c &lt; 7.0%). An HbA1c-only benchmark and three fixed blockwise logistic models were compared in the same complete-case cohort (n = 806). Internal validation used 1000 bootstrap resamples and reported optimism-corrected AUC, Brier score, calibration intercept, and calibration slope. Correlations, variance inflation factors (VIFs), nonlinear effects, decision-curve analysis, and a sensitivity analysis restricted to baseline HbA1c \u2265 7.0% were evaluated. Results: At baseline, 215 participants had HbA1c &lt; 7.0%; 179 maintained this status, 206 newly reached &lt;7.0%, 36 moved above the threshold, and 387 remained \u22657.0%. In complete cases, the optimism-corrected AUC was 0.868 (95% CI 0.844\u20130.892) for HbA1c alone and 0.870 (95% CI 0.848\u20130.893) for the full model. The corrected AUC difference between the full and HbA1c-only models was 0.001 (95% CI of \u22120.011 to 0.011). For the full model, the corrected Brier score was 0.146, the calibration intercept was 0.001, and the calibration slope was 0.925. VIFs were low (maximum of 1.33), although the TyG coefficient reversed direction after adjustment and was not interpreted causally. In participants with baseline HbA1c \u2265 7.0% (n = 592 complete cases), corrected AUCs were 0.850 for HbA1c alone and 0.849 for the full model. Conclusions: Baseline HbA1c accounts for nearly all discriminative performance. Added biomarkers and baseline therapeutic classes provide little internally validated incremental value, and the model should not be used for treatment decisions before external validation and prospective evaluation of clinical impact.<\/jats:p>","DOI":"10.3390\/diagnostics16193201","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:14:56Z","timestamp":1790936096000},"page":"3201","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of Six-Month Glycemic Status in Type 2 Diabetes: Development and Internal Validation of a Multivariable Model"],"prefix":"10.3390","volume":"16","author":[{"given":"Andreea Diana","family":"Igna","sequence":"first","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 1 University Street, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Bianca-L\u0103crimioara","family":"Petca","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 1 University Street, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Paula-Alexandra","family":"Popovici","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 1 University Street, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Ioana","family":"Moga","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Titus David","family":"Moga","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-1958","authenticated-orcid":false,"given":"Timea Claudia","family":"Ghitea","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Faculty of Medicine and Pharmacy, University of Oradea, 1 University Street, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0855-938X","authenticated-orcid":false,"given":"Corina","family":"Cinezan","sequence":"additional","affiliation":[{"name":"Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"visualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Mihaela Simona","family":"Popoviciu","sequence":"additional","affiliation":[{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41574-020-00425-6","article-title":"The trials and tribulations of determining HbA1c targets for diabetes mellitus","volume":"16","author":"Klara","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108011","DOI":"10.1016\/j.jdiacomp.2021.108011","article-title":"Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study","volume":"35","author":"Caballero","year":"2021","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S128\u2013S145.","DOI":"10.2337\/dc25-S006"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal Validation of Predictive Models: Efficiency of Some Procedures for Logistic Regression Analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Van Calster, B., McLernon, D.J., van Smeden, M., Wynants, L., and Steyerberg, E.W. (2019). Calibration: The Achilles Heel of Predictive Analytics. BMC Med., 17.","DOI":"10.1186\/s12916-019-1466-7"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision Curve Analysis: A Novel Method for Evaluating Prediction Models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum Sample Size for Developing a Multivariable Prediction Model: Part II\u2014Binary and Time-to-Event Outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Brata, R., Pascalau, A.V., Fratila, O., Paul, I., Muresan, M.M., Camarasan, A., and Ilias, T. (2024). Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review. Healthcare, 12.","DOI":"10.3390\/healthcare12232464"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.31083\/j.rcm2512436","article-title":"Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies","volume":"25","author":"Siam","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s13300-019-0625-3","article-title":"Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents","volume":"10","author":"Gentilella","year":"2019","journal-title":"Diabetes Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Popoviciu, M.S., Ghitea, T.C., Pantis, C., and Brata, R.D. (2026). Determinants of HbA1c Variability Across Clinical Subgroups: When the Same Value Does Not Reflect the Same Biological Risk. Medicina, 62.","DOI":"10.3390\/medicina62030451"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ekir.2017.11.009","article-title":"Glycated Albumin Versus HbA1c in the Evaluation of Glycemic Control in Patients With Diabetes and CKD","volume":"3","author":"Gan","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hung, C.C., Zhen, Y.Y., Niu, S.W., Lin, K.D., Lin, H.Y., Lee, J.J., Chang, J.M., and Kuo, I.C. (2022). Predictive Value of HbA1c and Metabolic Syndrome for Renal Outcome in Non-Diabetic CKD Stage 1-4 Patients. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081858"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-025-02751-3","article-title":"Relationship between stress hyperglycaemic ratio (SHR) and critical illness: A systematic review","volume":"24","author":"Song","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Joumaa, J.P., Raffoul, A., Sarkis, C., Chatrieh, E., Zaidan, S., Attieh, P., Harb, F., Azar, S., and Ghadieh, H.E. (2025). Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030727"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"He, Q., Ye, B., Li, H., Pan, Y., Du, Y., and Yang, K. (2025). Analysis of potential biomarkers for diabetic kidney disease and non-diabetic kidney disease based on urinary metabolomics analysis. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04544-y"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.2147\/IJGM.S572310","article-title":"The Association Between HbA1c Levels And Hematological Biomarkers in Adults with Type 2 Diabetes Mellitus: A Retrospective Study","volume":"18","author":"AlJedai","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_20","first-page":"e80736","article-title":"Correlation Between Glycated Hemoglobin (HbA1c) Levels and Lipid Profile in Patients With Type 2 Diabetes Mellitus at a Tertiary Hospital in Saudi Arabia","volume":"17","author":"AlZeer","year":"2025","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CLEP.S391749","article-title":"Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study","volume":"15","author":"Tan","year":"2023","journal-title":"Clin. Epidemiol."},{"key":"ref_22","first-page":"298","article-title":"Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI","volume":"96","author":"Chandrasekhar","year":"2020","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4093\/dmj.2026.0034","article-title":"Redefining \u03b2-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine","volume":"50","author":"Kim","year":"2026","journal-title":"Diabetes Metab. J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ozturk, S., and Akyol, E.M.B. (2026). Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine\/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria. J. Clin. Med., 15.","DOI":"10.3390\/jcm15135049"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, S., Wang, Q., and Yan, X. (2024). Association between triglyceride-glucose index and hypertension: A cohort study based on the China Health and Nutrition Survey (2009\u20132015). BMC Cardiovasc. Disord., 24.","DOI":"10.1186\/s12872-024-03747-9"},{"key":"ref_26","first-page":"e81550","article-title":"Triglyceride-Glucose Index and Atherogenic Index as Alternative Biomarkers for Glycemic Control in Type 2 Diabetes Mellitus","volume":"17","author":"Gajjar","year":"2025","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Demir, A.K., \u015eahin, \u015e., \u00c7\u0131t\u0131l, R., Demir, O., and \u00d6zmen, Z.C. (2025). Utility of TyG-Based Indices for Predicting Insulin Resistance in Turkish Adults: Insights from the TEKHAP Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14248965"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pafundi, P.C., Garofalo, C., Galiero, R., Borrelli, S., Caturano, A., Rinaldi, L., Provenzano, M., Salvatore, T., De Nicola, L., and Minutolo, R. (2021). Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020290"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rroji, M., Bob, F., Lo Cicero, L., Figurek, A., and Spasovski, G. (2026). Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures. Life, 16.","DOI":"10.3390\/life16071164"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/dom.14126","article-title":"Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial","volume":"22","author":"Mosenzon","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S.K., and Kirabo, A. (2025). Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1661563"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2641853","DOI":"10.1080\/0886022X.2026.2641853","article-title":"A multimodal predictive model incorporating transcriptomic-guided blood biomarkers and clinical variables for sepsis-associated acute kidney injury","volume":"48","author":"Wu","year":"2026","journal-title":"Ren. Fail."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Alagiakrishnan, K., Halverson, T., Olivares, D.V.F., and Sadowski, C.A. (2026). New Personalized Medicine Model for Medication Management. J. Pers. Med., 16.","DOI":"10.3390\/jpm16040182"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1038\/s41591-025-03849-7","article-title":"Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes","volume":"31","author":"Carletti","year":"2025","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2042018819875407","DOI":"10.1177\/2042018819875407","article-title":"Review of multimodal treatment for type 2 diabetes: Combining metabolic surgery and pharmacotherapy","volume":"10","author":"Sudlow","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/dme.12710","article-title":"Bioimpedance phase angle indicates catabolism in Type 2 diabetes","volume":"32","author":"Dittmar","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_37","first-page":"494","article-title":"Effect of early glycemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic review and meta-analysis","volume":"20","author":"Barrett","year":"2019","journal-title":"Pediatr. Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rodgers, L.R., Hill, A.V., Dennis, J.M., Craig, Z., May, B., Hattersley, A.T., McDonald, T.J., Andrews, R.C., Jones, A., and Shields, B.M. (2021). Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: A cohort study. BMC Med., 19.","DOI":"10.1186\/s12916-021-02054-w"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3201\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:18Z","timestamp":1790936298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":38,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["diagnostics16193201"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16193201","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}